R
Ryvu Therapeutics SA
WSE:RVU
Ryvu Therapeutics SA
WSE:RVU
Price:
24.5
PLN
2.08%
Market Closed
Market Cap:
zł566.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
PL |
|
S
|
Summa Linguae Technologies SA
WSE:SUL
|
PL |
|
Vakrangee Limited
NSE:VAKRANGEE
|
IN |
|
Ora Gold Ltd
ASX:OAU
|
AU |
|
P
|
PVI Holdings
VN:PVI
|
VN |
|
Toho Gas Co Ltd
TSE:9533
|
JP |
|
TKO Group Holdings Inc
NYSE:TKO
|
US |
Balance Sheet
Balance Sheet Decomposition
Ryvu Therapeutics SA
Ryvu Therapeutics SA
Balance Sheet Decomposition is not available for
Ryvu Therapeutics SA
Ryvu Therapeutics SA
Balance Sheet
Ryvu Therapeutics SA
Ryvu Therapeutics SA
Currency: PLN
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
5
|
5
|
5
|
29
|
29
|
36
|
110
|
72
|
93
|
83
|
265
|
10
|
160
|
60
|
|
| Cash |
5
|
5
|
0
|
11
|
29
|
36
|
110
|
26
|
93
|
47
|
22
|
10
|
160
|
60
|
|
| Cash Equivalents |
1
|
0
|
5
|
18
|
0
|
0
|
0
|
46
|
0
|
36
|
243
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
68
|
5
|
1
|
176
|
66
|
48
|
|
| Total Receivables |
3
|
0
|
10
|
18
|
16
|
20
|
58
|
15
|
8
|
12
|
17
|
33
|
36
|
20
|
|
| Accounts Receivables |
1
|
0
|
7
|
13
|
10
|
10
|
14
|
2
|
2
|
6
|
1
|
9
|
16
|
11
|
|
| Other Receivables |
2
|
0
|
3
|
5
|
6
|
10
|
44
|
13
|
6
|
6
|
16
|
24
|
20
|
10
|
|
| Inventory |
0
|
0
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
1
|
1
|
|
| Other Current Assets |
0
|
0
|
1
|
1
|
1
|
2
|
2
|
1
|
2
|
2
|
4
|
10
|
10
|
10
|
|
| Total Current Assets |
9
|
0
|
17
|
49
|
48
|
60
|
173
|
90
|
172
|
104
|
368
|
278
|
272
|
139
|
|
| PP&E Net |
5
|
0
|
7
|
9
|
22
|
31
|
52
|
66
|
91
|
91
|
82
|
78
|
73
|
70
|
|
| PP&E Gross |
5
|
0
|
7
|
9
|
22
|
31
|
52
|
66
|
91
|
91
|
82
|
78
|
73
|
70
|
|
| Accumulated Depreciation |
5
|
0
|
9
|
13
|
16
|
21
|
29
|
21
|
28
|
44
|
52
|
62
|
72
|
72
|
|
| Intangible Assets |
0
|
0
|
0
|
2
|
6
|
2
|
2
|
3
|
2
|
3
|
4
|
6
|
8
|
6
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
3
|
2
|
23
|
24
|
29
|
29
|
20
|
23
|
25
|
9
|
|
| Other Long-Term Assets |
2
|
0
|
2
|
6
|
10
|
8
|
5
|
1
|
1
|
1
|
0
|
17
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
17
N/A
|
0
N/A
|
27
N/A
|
65
+143%
|
89
+37%
|
104
+16%
|
256
+147%
|
184
-28%
|
296
+61%
|
229
-23%
|
475
+108%
|
403
-15%
|
379
-6%
|
224
-41%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
2
|
0
|
5
|
4
|
7
|
9
|
16
|
22
|
11
|
14
|
14
|
25
|
33
|
18
|
|
| Accrued Liabilities |
2
|
0
|
1
|
2
|
4
|
2
|
3
|
3
|
5
|
5
|
12
|
12
|
12
|
4
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
1
|
0
|
2
|
2
|
3
|
3
|
3
|
3
|
2
|
1
|
27
|
17
|
|
| Other Current Liabilities |
4
|
0
|
9
|
10
|
6
|
14
|
13
|
2
|
15
|
14
|
17
|
32
|
36
|
23
|
|
| Total Current Liabilities |
8
|
0
|
15
|
16
|
19
|
27
|
36
|
31
|
34
|
36
|
45
|
70
|
108
|
62
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
8
|
6
|
10
|
6
|
4
|
10
|
11
|
9
|
84
|
79
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
1
|
5
|
5
|
6
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
2
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
3
|
0
|
2
|
2
|
6
|
6
|
11
|
21
|
28
|
20
|
76
|
65
|
43
|
30
|
|
| Total Liabilities |
11
N/A
|
0
N/A
|
18
N/A
|
19
+7%
|
34
+80%
|
41
+22%
|
64
+55%
|
63
-1%
|
72
+14%
|
68
-6%
|
132
+95%
|
144
+9%
|
235
+64%
|
171
-27%
|
|
| Equity | |||||||||||||||
| Common Stock |
4
|
0
|
4
|
5
|
5
|
6
|
6
|
6
|
7
|
7
|
7
|
9
|
9
|
9
|
|
| Retained Earnings |
2
|
0
|
5
|
16
|
25
|
31
|
31
|
290
|
258
|
196
|
378
|
66
|
50
|
140
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
25
|
25
|
25
|
155
|
145
|
279
|
279
|
279
|
520
|
520
|
520
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
321
|
321
|
321
|
321
|
335
|
335
|
335
|
|
| Total Equity |
6
N/A
|
0
N/A
|
9
N/A
|
46
+399%
|
55
+19%
|
62
+13%
|
192
+208%
|
121
-37%
|
224
+86%
|
161
-28%
|
343
+113%
|
260
-24%
|
144
-45%
|
54
-63%
|
|
| Total Liabilities & Equity |
17
N/A
|
0
N/A
|
27
N/A
|
65
+143%
|
89
+37%
|
104
+16%
|
256
+147%
|
184
-28%
|
296
+61%
|
229
-23%
|
475
+108%
|
403
-15%
|
379
-6%
|
224
-41%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
11
|
0
|
11
|
13
|
13
|
14
|
16
|
16
|
18
|
18
|
18
|
23
|
23
|
23
|
|
Switch to:
Switch to:
See Also
Discover More
